Preoperative high-sensitivity C-reactive protein predicts depression in patients undergoing coronary artery bypass surgery: A single-center prospective observational study  by Yang, Limeng et al.
P
M
Perioperative Management Yang et alPreoperative high-sensitivity C-reactive protein predicts
depression in patients undergoing coronary artery bypass
surgery: A single-center prospective observational studyLimeng Yang, MD, Jianyang Wang, MD, Lu Zhang, MD, Jianfeng Hou, MD,
Xin Yuan, MD, PhD, Shengshou Hu, MD, PhD, and Zhe Zheng, MD, PhDFrom th
tional
Chine
China
Funding
Publi
search
Minis
Disclosu
Ethics
Cardi
L.Y., J.W
Receive
public
Address
jing,
0022-52
Copyrig
doi:10.1
500Objective: Our objective was to reveal the contribution of preoperative high-sensitivity C-reactive protein
(hsCRP) levels to the risk of depression in patients undergoing coronary artery bypass grafting (CABG).
Methods: In this study, 232 consecutive patients undergoing elective CABG were evaluated for depression
utilizing the 9-item Patient Health Questionnaire scale at least 3 days before surgery and 6 months after
CABG. In addition, peripheral blood samples were collected at baseline and the circulation levels of hsCRP
were measured.
Results: The preoperative and postoperative rate of depression was 18.1%. Interestingly, preoperative depres-
sion was independently associated with women (odds ratio [OR], 2.49; 95% confidence interval [CI], 1.13-5.50)
and log-transformed hsCRP (OR, 1.16; 95% CI, 1.06-1.27) after adjusting for various factors using logistic
regression, including age, sex, and university-level education. Postoperative depression was only associated
with log-transformed hsCRP (OR, 1.15; 95%CI, 1.05-1.25) in these patients. Log-transformed hsCRP remained
associated with future depression after adjusting for postoperative medications or major adverse cardiovascular
events during the follow-up period.
Conclusions: The present study is the first to report elevated serum hsCRP is an independent predictor for
depression in CABG patients not only preoperatively but also up to 6 months after surgery. These clinical
findings may reveal a potential target for improving prognosis in CABG patients with depression. (J Thorac Car-
diovasc Surg 2012;144:500-5)Depression is frequently observed in patients with coronary
heart disease (CHD)1 and represents a significant risk factor
for major cardiovascular events.2 Depression in patients
with existing CHD confers a relative risk between 1.5
and 2.5 for cardiac morbidity and mortality.3 In previous
cross-sectional and prospective studies, the prevalence
of major depression in patients with CHD ranged from
10% to 47%,4 and slightly higher rates were reported
(28%) in patients requiring coronary artery bypass grafting
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The Journal of Thoracic and Cardiovascular Surgincrease mortality after bypass surgery5 and were associ-
ated with atherosclerotic progression.6 In 2008, the Ameri-
can Heart Association recommended routine screening for
depression in patients with CHD in various settings,
including the hospital, physician’s office, clinic, and cardiac
rehabilitation center.7
In recent years, growing evidence also suggests the
existence of a bidirectional relationship between depressed
mood and inflammation.8,9 Dantzer and associates10 (2008)
reported that inflammation can lead to the development of
symptoms of depression in vulnerable individuals. Consis-
tent with these findings, high-sensitivity C-reactive protein
(hsCRP), currently as one available clinical biomarker of
inflammation, was reported associated with increased
long-term mortality and extended hospital length of stay
in patients undergoing nonemergency CABG-only
surgery.11 The latest research has proved the association
between depression and C-reactive protein in healthy
adults.12 However, the contribution of hsCRP to depression
remains poorly understood in patients requiring CABG. To
date, previous studies reported several risk factors for
depression in CABG patients, including age,13 female
gender,14 and education.15 Therefore, the primary purpose
of our study was to investigate the predictive value of
preoperative hsCRP as a risk marker for major depression
in CABG patients before surgery and 6months after CABG.ery c August 2012
FIGURE 1. Participants available for analysis from the study. PHQ, Pa-
tient Health Questionnaire scale.
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CHD ¼ coronary heart disease
CI ¼ confidence interval
hsCRP ¼ high-sensitivity C-reactive protein
In-hsCRP ¼ log-transformed high-sensitivity
C-reactive protein
MACE ¼ major adverse cardiac event
OR ¼ odds ratio
PHQ ¼ Patient Health Questionnaire scale
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Study Population
This study was designed as a prospective observational study to identify
the contribution of blood hsCRP to depressive symptoms among patients
undergoing CABG surgery. Therefore, the data were prospectively
collected from a consecutive series of patients undergoing their first bypass
operation at Fuwai Hospital in Beijing, China. In brief, 258 consecutive
patients who underwent first-time elective CABG from March 2010 to
September 2010 at Fuwai Hospital were approached to participate in this
study. The exclusion criteria included the following subjects: (1) less
than 18 years of age, (2) subjects with previous CABG, and (3) a language
barrier preventing questionnaire completion. The remaining cohort of 234
patients who underwent first-time elective CABG was eligible for the
study. Of them, 2 patients died during hospitalization. This study was
approved by the local ethics committee, and all participants of the study
were voluntary and provided written informed consent.
Each participant completed the baseline evaluation at least 3 days before
CABG, including depressive symptoms, medical history, physical exami-
nation, use of medications, and collection of fasting blood samples. Addi-
tional information was collected by telephone 6 months later, including
postoperative medications (aspirin, b-blockers, or statin use) and major
adverse cardiac events (MACEs: all-cause death, nonfatal myocardial
infarction, and any target-vessel revascularization). In addition, depressive
symptoms were assessed by the 9-item Patient Health Questionnaire scale
(PHQ) at baseline and 6months after surgery. At last, 232 participants com-
pleted the whole study with no patients lost during the follow-up period.
Assessment of Depressive Symptoms
Depressive symptoms were assessed with the 9-item PHQ16 during
hospitalization at least 3 days before CABG, as well as 6 months after
surgery via telephone contact. PHQ-9 is a 9-item self-administered instru-
ment to assess depressive symptoms over the past 2 weeks that maps 9
symptoms from the Diagnostic and Statistical Manual of Mental Disorders,
edition 4, classification for major depressive disorder.16 Previous studies
have established PHQ-9 as a valid tool for depression screening17 and it
seems reliable and valid for detecting major depressive disorder in Chinese
patients.18 Telephone administration of the PHQ-9 appeared to generate
a reliable procedure for assessing depression.19 PHQ-9 score provides
a continuous score of depressive symptom severity range from 0 to 27.
Patients had to score 10 or more, indicating a moderate to severe level of
depressive symptoms. For this study, we chose PHQ-9 of 10 or more as
the screening cutoff point for the diagnosis of major depression, inasmuch
as a PHQ-9 score of at least 10 had a sensitivity and specificity of 88% for
a clinical diagnosis of major depression.17
Measurement of hsCRP
Blood samples collected at baseline were stored at80C until protein
analyses were performed. The circulation levels of hsCRP were assessedThe Journal of Thoracic and Caby the high-sensitivity nephelometric method (Dade Behring Marburg
GmbH, Marburg, Germany) that displays a detection limit of 0.1 mg/L.
The intra-assay precision (coefficient of variation) was less than 5.5%
and the interassay coefficient of variation was less than 8.2% in our
laboratory.
Statistical Analysis
For descriptive purpose, categorical data were expressed as frequencies
and continuous data are reported as mean and standard deviation (mean 
standard deviation). The continuous variables and frequencies between
groups were compared by the Student t test and c2 or Fisher exact test.
Owing to the skewed distribution of hsCRP, it was log transformed for anal-
yses. Binary logistic regression was used to estimate the odds ratio (OR) of
log-transformed hsCRP (In-hsCRP) to the major depression in patients
undergoing CABG.17 We successfully adjusted demographic data (age,
gender) and the possible confounding effects of some social characteristics
(university-level education), obesity, clinical characteristics (diabetes,
hypertension, chronic pulmonary disease, valve lesion, cerebrovascular
accident, and recent myocardial infarction), cardiac functional status
(New York heart Association classes, left ventricular ejection fraction),
and statin use. The aforementioned 13 adjustment factors include the
following: the factors that had been revealed in previous studies—age,13
gender,14 university-level education,15 obesity20—and other factors that
indicated the disease severity of patients—clinical characteristics and
aforementioned cardiac functional status, that is, preoperative statin use
considering the effect of statins on hsCRP levels.21 For the follow-up
results, MACE as a potential risk factor of major depression was added
into the multivariate analysis model. The optimal cutoff value of hsCRP
for major depression with the combination of the highest sensitivity and
specificity was obtained by receiver operating characteristic curve. All tests
for statistical significance were 2-tailed with a ¼ .05. All analyses were
performed with SPSS Package for Windows version 13.0 (SPSS, Inc,
Chicago, Ill).RESULTS
Baseline Characteristics
In this study, 232 patients completed all questionnaires
at baseline and up to 6 months after CABG surgery
(Figure 1). No patients died or were lost during the
6-month follow-up questionnaire. The mean age of these
patients was 60.8  8.6 years, and the majority of the
patients were male (81.5%). Among the patients, 155
(66.8%) had a history of hypertension, and 67 (28.9%)
had diabetes mellitus. Additionally, 104 (44.8%) patientsrdiovascular Surgery c Volume 144, Number 2 501
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Mexhibited recent myocardial infarction during the 3-week
period before the operation, and 28 (12.1%) patients also
had valve disease. Of the participants, 38.8% (90/232)
were treated with statin medication more than 1 month be-
fore surgery, a rate that was higher than previously re-
ported.8 Compared with nondepressed patients, depressed
patients were more often female, had a low education
level, and had a cerebrovascular accident or valve lesion
(Table 1).
Depression Evaluation Outcomes
PHQ-9 scores ranged from 0 to 21 preoperatively and
from 0 to 23 at follow-up assessment. The mean value of
PHQ-9 scores was 4.8  5.0 at baseline and 4.2  5.0 at
6 months after surgery. A total of 42 (18.1%) had major
depression (PHQ-9  10) preoperatively. During the
6-month follow-up questionnaire, 42 (18.1%) fulfilled the
diagnosis of major depressive disorder. Likewise, we found
a higher frequency of depressive symptoms in women than
men both preoperatively (30.2% vs 15.3%; P ¼ .022) and
postoperatively (20.9% vs 17.5%; P¼ .594). Although the
occurrence of depressive symptoms was similar preopera-
tively and postoperatively, we observed obvious changes
in individuals (Figure 2). No significant depressive symp-
toms (PHQ-9< 10) before or after surgery were found in
72.7% (169/232). New-onset depression occurred in
9.1% (21/232), transient depression in 9.1% (21/232),
and persistent depression in 9.1% (21/232). The levels of
hsCRP are shown in Figure 3. Results indicated that signif-
icant difference in hsCRP levels were observed in patients
with the ollowing 4 depression status: never depression,
new-onset depression, transient depression, and persistent
depression.TABLE 1. Characteristics of CABG patients with and without major depr
Variables
Preoperative depression
No (n ¼ 190) Yes (n ¼ 42)
Age, y 60.4  8.4 62.5  9.1
Female,% 15.8 31.0
University-level education,% 18.9 17.1
BMI, kg/m2 25.5  2.8 25.7  3.0
Diabetes mellitus,% 29.5 26.2
Hypertension,% 65.3 73.8
Chronic pulmonary disease,% 2.1 0.0
Valve lesion,% 10.5 19.0
CVA,% 11.1 11.9
Recent MI* 44.7 45.2
NYHA classes I/II/III,% 9.5/81.6/8.9 4.8/76.2/19.0
LVEF,% 59.4  9.4 57.8  9.4
Statin use,%y 36.3 50.0
hsCRP, mg/L 3.0  2.8 5.0  5.2
Data are expressed as means  standard deviation. CABG, Coronary artery bypass graftin
NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; hsCRP, high
statins more than 1 month before surgery. zP<.05.
502 The Journal of Thoracic and Cardiovascular SurgPostoperative Medications and MACE in CABG
Patients With and Without Depression at 6 Months’
Follow-up
Table 2 presents the postoperative medications and the
MACE rate in patients with and without depression during
the 6-month follow-up. None of the patients used selective
serotonin reuptake inhibitors at all during the study. No sig-
nificant difference was detected in postoperative medica-
tions between depressed patients and nondepressed
patients including aspirin, b-blockers, and statins. The inci-
dence of MACE was 4.3%. Compared with nondepressed
patients, depressed patients displayed higher rates of nonfa-
tal myocardial infarction (0.0% vs 7.1%; P ¼ .006), any
target-vessel revascularization (0.0% vs 4.8%; P ¼ .032),
and MACE (2.6% vs 11.9%; P ¼ .024).
In all participants, univariate analysis demonstrated an
association between depression symptoms and an increased
incidence of MACE (Table 2). However, addition of MACE
in model 2 (Table 3) results indicated that the contribution
of MACE to postoperative depression was not observed in
CABG patients (OR, 4.46; 95% confidence interval [CI],
0.89-22.37).
Contribution of hsCRP to Depression
We investigated the contribution of hsCRP to the risk of
depressive symptoms, and the results of the regression anal-
ysis are presented in Table 3. Multivariate analysis revealed
that each standard deviation increase in In-hsCRP was asso-
ciated with an increased OR for depression (preoperatively:
OR, 1.16; P ¼ .001; 6 months’ follow-up: OR, 1.15;
P ¼ .002), and hsCRP was correlated with depression
both preoperatively and 6months after surgery. Considering
the possible influence of adverse cardiac events andession
Postoperative depression
P value No (n ¼ 190) Yes (n ¼ 42) P value
.166 60.9  8.4 60.2  9.5 .643
.022z 17.9 21.4 .594
.780 20.0 11.9 .222
.580 25.5  2.8 25.7  3.0 .710
.671 29.5 26.2 .671
.287 67.9 61.9 .456
1.000 1.6 2.4 .553
.125 11.6 14.3 .626
1.000 14.3 20.6 .485
.953 43.7 50.0 .456
.114 7.4/81.6/11.0 14.3/76.2/9.5 .349
.310 59.3  9.1 58.2  10.7 .467
.100 37.9 42.9 .550
.021z 3.0  3.0 4.9  4.7 .015z
g; BMI, body mass index; CVA, cerebrovascular accident; MI, myocardial infarction;
-sensitivity C-reactive protein. *Three weeks before surgery. yRegular application of
ery c August 2012
FIGURE 2. Numbers of patients with depression at baseline and 6 months
after bypass surgery. The gray bars indicate the numbers of patients with
a PHQ-9 score lessthan 10; the black bars indicate the number of patients
with depression defined by a PHQ-9 score of 10 ormore. Labels on the right
show the different classifications based on depressive symptoms preopera-
tively and postoperatively—never, new onset, transient, and persistent.
PHQ, Patient Health Questionnaire scale.
TABLE 2. Postoperative medications and MACE in patients with and
without depression at 6 months after CABG
Postoperative depression
P value
No (%)
(n ¼ 190)
Yes (%)
(n ¼ 42)
Postoperative medications
Aspirin 76.8 76.2 .928
b-blockers 87.9 88.1 .971
Statins 16.3 19.5 .668
Adverse cardiac events
All cause death 0.0 0.0 
Nonfatal MI 0.0 7.1 .006*
Target-vessel
revascularization
0.0 4.8 .032*
MACE 2.6 11.9 .024*
MACE (major adverse cardiac event) is defined as all-cause death, nonfatal myocar-
dial infarction (MI), or any target-vessel revascularization (percutaneous coronary
intervention and/or coronary artery bypass grafting [CABG]). *P<.05.
Yang et al Perioperative Managementpostoperative medications on postoperative depression, we
also additionally adjusted for postoperative medications
(aspirin, b-blockers, and statin use) and MACE in model
2. We obtained similar results, concluding that the In-
hsCRP (OR. 1.14; 95% CI, 1.04-1.25) remained an inde-
pendent predictor for postoperative major depression.
Further analyses were done, and the baseline depressive
symptoms (PHQ-9 scores) were added into model 2
(Table 3). Results showed that baseline PHQ-9 scores
were significantly associated with the postoperative depres-
sion (OR, 1.09; 95% CI, 1.06-1.35). When the 2 risk factors
baseline PHQ-9 and hsCRP were put into the same
model (model 2), both PHQ-9 scores (OR, 1.04; 95% CI,
1.01-1.17) and hsCRP (OR, 1.13; 95% CI, 1.05-1.25)FIGURE 3. High-sensitivity C-reactive (hsCRP) protein levels in patients
with 1 of the 4 stages of depression.
The Journal of Thoracic and Cawere independently associated with the postoperative
depression.
Preoperative elevations in hsCRP levels were analyzed as
a continuous variable as a risk predictor for depression in
this study. In our study, the best cutoff point was not
obtained through the receiver operating characteristic
curve, and we observed that participants with higher levels
of hsCRP had more serious depressive symptoms. The area
under the receiver operating characteristic curve for hsCRP
in the prediction of depression preoperatively and postoper-
atively is presented in Table 4. The analysis indicated that
the predictive function of hsCRP for preoperative depres-
sion is best in patients with an hsCRP level more than
2.5 mg/L (area under the curve¼ 0.795); thereby, this anal-
ysis is excellent in patients with an hsCRP level of 3.0 mg/L
or more (area under the curve ¼ 0.704) for postoperative
depressive symptoms.
Considering the anti-inflammatory effects of drugs,
statins were treated as a potential confounder in this
study.21 Consistent with the pharmacokinetic principle,
preoperative statin use was defined as preoperative regular
application of statins for more than 1 month. A high rateTABLE 3. Multivariable-adjusted OR of depression associated with
hsCRP
Regression model, OR (95% CI)
Base model Model 1 Model 2
Preop 1.15 (1.06-1.26) 1.15 (1.06-1.26) 1.16 (1.06-1.27)
Postop 1.26 (1.08-1.47) 1.15 (1.05-1.25) 1.15 (1.05-1.25)
Base model was adjusted for age and gender.Model 1 was adjusted for the variables in
base model plus social risk factors including university-level education. Model 2 was
adjusted for all variables in model 1 plus obesity (body mass index>30.0), diabetes,
hypertension, chronic pulmonary disease, valve lesion, cerebrovascular accident,
New York Heart Association functional classification, left ventricular ejection
fraction, and statin use. High-sensitivity C-reactive protein was log transformed for
analysis. OR, Odds ratio; hsCRP, high-sensitivity C-reactive protein; CI, confidence
interval.
rdiovascular Surgery c Volume 144, Number 2 503
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TABLE 4. hsCRP predict depression for CABG patients with different hsCRP levels
hsCRP levels (mg/L)
<1.0 1.0 <1.5 1.5 <2.0 2.0 <2.5 2.5 <3.0 3.0
n 43 189 90 142 112 120 137 95 153 79
Area under ROC Preop 0.482 0.582 0.480 0.630 0.539 0.763 0.463 0.795 0.406 0.742
Postop 0.425 0.621 0.531 0.673 0.482 0.656 0.489 0.698 0.481 0.704
hsCRP, High-sensitivity C-reactive protein; CABG, coronary artery bypass grafting; ROC, receiver operating characteristic.
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ulation (38.8% at baseline). Univariate analysis indicated
no significant difference in statin use among the depressed
patients and those without depression preoperatively
(50.0% vs 36.3%; P ¼ .100) and postoperatively
(19.5% vs 16.3%; P ¼ .668). Furthermore, multivariate
analysis showed that preoperative and postoperative statin
medication use was not associated with depressive mood
in CABG patients (model 2, preoperatively: OR, 1.82;
95% CI, 0.88-3.78; P ¼ .106; postoperatively: OR,
1.34; 95% CI, 0.65-2.76; P ¼ .433). Inasmuch as none
of our study participants with depressive symptoms used
selective serotonin reuptake inhibitors during this whole
study, we did not adjust for selective serotonin reuptake
inhibitor antidepressants as a confounding factor in the
study.
DISCUSSION
The present prospective study evaluated the predictive
value of preoperative circulation hsCRP for major depres-
sion in patients undergoing CABG. A direct relationship
was observed in that the higher hsCRP levels were associ-
ated with a higher risk of having major depression for
CABG patients. Data from our study demonstrated that pre-
operative depression was associated with an increased risk
ranging from 15% to 16% for each standard deviation
increase in In-hsCRP. For postoperative depression the
increased risk ranged from 15% to 26% in this group as
described in Table 3.
These findings also suggest that inflammation may play
an important role in the pathophysiology of depression in
CABG patients. There were some other psychophysiologic
factors that had been revealed in previous studies such as
autonomic nervous system22 and serotonin metabolism.23
Although the bidirectional association between depression
and cardiovascular disease is widely documented, as both
depression and CHD are heterogeneous diseases, it is
unlikely that a single psychophysiologic factor will explain
a substantial proportion of the prospective association
between depression and CHD owing to the complexity of
the network of systems involved.24 Further study will be
needed to explore the role of hsCRP in the pathophysiologic
mechanisms of major depression and confirm whether
hsCRP can serve as a therapeutic target for depression in
CABG patients.504 The Journal of Thoracic and Cardiovascular SurgTo date, depression as a major risk factor for patients after
CABG surgery had been consistent in the literature.6 Like-
wise, risk factors for depression such as age,13 gender,14
university-level education,15 and obesity20 were confirmed
in this previous research. Although some studies had
explored the relationship between hsCRP and major depres-
sion in patients with CHD, these studies did not adjust for
the recognized risk factors mentioned herein. Therefore,
our study clearly assessed the prediction function of hsCRP
for depression among CABG patients using logistic regres-
sion models.
In previous studies,8 the utilization rate of statins was
lower in the study participants than in our patients. We
believe the possible reason may be the inherent differences
between the CHD patients and CABG patients, who usually
had more serious lesions in the coronary arteries than is
common for patients with CHD. However, we get similar
results that the proportion of patients treated with statins
tends to be higher in patients with depressive symptoms
(Tables 1 and 2).
In this study, as the primary study objective of our study,
we did not further explore the contribution of depression to
MACE in CABG patients. However, considering the poten-
tial effect of MACE on postoperative depression, we also
added MACE as a confounding factor in model 2, and anal-
ysis showed that it did not change the result. Furthermore,
our finds indicated that the risk of MACE in CABG patients
with preoperative major depression should be discussed
when obtaining the patient’s informed consent by cardiac
surgeons and postoperative follow-up was needed. Depres-
sion recognition and management may improve outcomes
in these patients.
As mentioned earlier, both hsCRP and depression are
significant risk factors of poor outcomes for patients
undergoing CABG.5,11 Our findings have proved the
independent association between the 2 factors. Further
study will be needed to examine whether hsCRP can serve
as a therapeutic target for depression in CABG patients. If
the results are positive, it would be of great clinical
significance for the improvement of outcomes in depressed
patients undergoing bypass surgery.
Limitations
There are potential limitations to our study. First, we could
not obtain biochemical results from these participantsery c August 2012
Yang et al Perioperative Managementinasmuch as the follow-up was completed via telephone
contact. Therefore, future studies may be required to
explore the association between the continued changes of in-
flammatory proteins and the severity of depressive symptoms
in CABG patients. Second, we investigated only a single
measure of systemic inflammation, and some other possible
associated inflammatory markers such as interleukin-6,
tumor necrosis factor-a, and interferon-g25were not included
in this study. Another limitation of our study is that it is
a single-center study. Although this study was conducted at
a single center, Fuwai Hospital, the participants of this study
were from several different areas of China, so no regional
selection bias existed in this research. Nonetheless, the
present study designed with a prospective observation
method could exclude the effect of possible selection biases.
CONCLUSIONS
Our study suggests that hsCRP displays a consistent and
significant prognostic value for major depression in CABG
patients both preoperatively and 6 months after surgery.
These findings could ultimately be used to improve the
prognosis of depressed patients after CABG.
We acknowledge the participants in this study as well as the
physicians, nurses, and administrative staff at Fuwai Hospital
who assisted with various aspects of this study. We also thank Li
He and Huan Ren for their tireless efforts in blood sample
collection.
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